A NCA analysis of approval documents Paul AF Jansen, geriatrician, - PowerPoint PPT Presentation

A NCA analysis of approval documents Paul AF Jansen, geriatrician, clinical pharmacologist Dep Geriatrics and Ephor, UMC Utrecht, The Netherlands 23 March 2012

Pre-authorization studies and the users of medicines Number of prescriptions in 2009 in the Netherlands

Benefit/risk is changing • Evidence for benefit of several medicines • Time until benefit is shorter compared to younger adults • Safety is a problem because of changes in PK/PD • Nerve system damage is important • Decrease in kidney function • Decreased balance • Decreased thirst etc.

The consequences: HARM frail patients are at risk to be admitted to hospital because of ADR • Cognitive disturbance (HR 11,9; 3,9-36,3) • Polymorbidity > 5 (HR 8,7; 3,1-24,1) • decreased kidney function (HR 3,1; 1,9- 5,2) • not living independently (HR 3,0;1,4-6,5) • Polypharmacy (>5 HR 2,7; 1,8-3,9) • Adherence problems (HR 2,3; 1,4-3,8) Leendertse et al. Arch Int Med 2008;168: 1890-6

Is it true that older patients are not studied? • Which information is available in the SmPC for appropriate prescribing in older persons? Erna Beers Prof Bert Leufkens • Which information is available in Prof Toine Egberts Dr Paul Jansen the EPAR for appropriate prescribing in older persons? www.ephor.eu • What is the compliance with the almost 20 year old ICH E7 guideline?

Methods • All non-generic products with a European centralised marketing authorisation between 2008 and 2011 with complete dossiers, indicated for diseases in older individuals • The ICH E7 guideline was summarised in 19 items

19 items of the ICH E7 • Nature of the studied population ( 4 items) • Inclusion >65 and >75 years • Exclusion based on age • Exclusions based on common co-morbidity • Clinical experience in older patients (4 items) • Number >65 years • Age-related differences for efficacy, dose-response and adverse events • Pharmacokinetic studies (8 items) • Drug-drug interaction studies (3 items)

Subdivision of available and missing information

Results • 53 medicinal products • Neoplasms : 12 (23%) • Musculoskeletal system/connective tissue: 10 (19%) • Circulatory system: 8 (15%) • Endocrine, nutritional and metabolic diseases: 5 (9%) • Infectious diseases: 5 (9%) • Others: 13 (25%)

Available, positive information

Available, positive information per category

Non-available information that should have been positive

Non-available information that should have been positive per category

Conclusions • Information on older persons, according to the ICH E7 is relatively high available in the EPARs • However it is often not present in the SmPC • Especially information on common co-morbidities, on age-related differences in efficacy and kind of PK study in older persons are lacking

Discussion: is the ICH E7 information what prescribers want? • Delphi study on the Information of Medicine appropriateness in the Elderly (DIME) • Regulators found several items less important compared to geriatricians/other experts: • The convenience of use for older persons (dosage form and packaging) • The extent of renal clearance of the active substances in old persons • No exclusion based on concomitant medical conditions common in old persons

What was left out of the final Dime? • No exclusion based on concomitant medical conditions common in old persons • A single-dose pharmacokinetic study in young versus old persons

DIME: extra items are needed (total items: 26) • No exclusion based on concomitant treatment with drugs commonly prescribed for old persons • The post-marketing data collection in geriatric patients is specified in the Risk Management Plan • The extent of drug accumulation in old persons • Information should be available about dosing instructions • The convenience of use for older persons

DIME: extra items are needed, especially about safety • Potential anticholinergic effects • Potential sedative effects • Potential orthostatic effects • Potential effects on the locomotor system • Potential cardiovascular side effects • Potential effects on haemostasis • Important drug-disease interactions

Final item list of the DIME Information should be available on: ICH E7 Q&A X Inclusion of patients >65 years in phase III studies X Inclusion of patients >75 years in phase III studies X For drugs used in diseases not unique for, but present in, old persons: inclusion of at least 100 patients >65 years in the phase III studies X For drugs used in diseases characteristically associated with aging (e.g. Alzheimer's disease): the majority of the clinical database consists of geriatric patients X No exclusion of patients on the basis of an upper age cut-off X No exclusion based on concomitant treatment with drugs commonly prescribed for old persons X The post-marketing data collection in geriatric patients is specified in the Risk Management Plan

Final item list PHARMACOKINETICS Information should be available on: ICH E7 Huisman et al. X A multiple-dose pharmacokinetic study in young versus old persons, if there are age-related differences in pharmacokinetics X The extent of drug accumulation in old persons X The extent of renal clearance of the active substances (i.e. parent compound and/ or metabolites) in old persons X The extent of hepatic clearance of the active substances (i.e. parent compound and/ or metabolites) in old persons X The therapeutic dose range of the drug X The extent of metabolism via or effects on specified CYP450 enzymes X Potential drug-drug interactions, if the therapeutic range of the drug or likely concomitant drugs is narrow, and the likelihood of the concomitant therapy is great Huisman et al. Drugs and Aging 2011; 28: 391-402

Final item list EFFICACY Information should be available on: ICH E7 X Age-related differences in efficacy X Age-related differences in dose-response

Final item list SAFETY Information should be available on: ICH E7 Huisman et al. X Age-related differences in adverse events X Potential anticholinergic effects (e.g. cognitive decline, delirium, blurred vision, urine retention) X Potential sedative effects X Potential orthostatic effects X Potential effects on the locomotor system (e.g. decline of mobility, increased incidence of falls) X Potential cardiovascular side effects (e.g. arrhythmias, ischemic effects) X Potential effects on haemostasis (e.g. thrombotic effects, bleeding risk) X Important drug-disease interactions (e.g. exacerbation of heart failure)

Final item list CONVENIENCE OF USE Information should be available on: Huisman Delphi et al. panel X The convenience of use for older persons (dosage form and packaging) X Information should be available about dosing instructions